Article: Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one

Statins are promising anticancer agents that target the mevalonate pathway. Tumor cells are sensitive to depletion of mevalonate-derived products but this activity triggers a homeostatic feedback loop that blunts statin efficacy. We showed that dipyridamole inhibits this feedback response and potentiates statin antitumor activity. This study identifies statins plus dypridamole as a preclinically effective combination of approved agents.

Citing Articles

Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin-Dipyridamole Combination Treatment in Melanoma Cell Lines.

Irie N, Mizoguchi K, Warita T, Nakano M, Sasaki K, Tashiro J Biomedicines. 2024; 12(3).

PMID: 38540310 PMC: 10968169. DOI: 10.3390/biomedicines12030698.

Lipid Regulatory Proteins as Potential Therapeutic Targets for Ovarian Cancer in Obese Women.

Yang J, Stack M Cancers (Basel). 2020; 12(11).

PMID: 33233362 PMC: 7700662. DOI: 10.3390/cancers12113469.

Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.

Gobel A, Breining D, Rauner M, Hofbauer L, Rachner T Cell Death Dis. 2019; 10(2):91.

PMID: 30692522 PMC: 6349912. DOI: 10.1038/s41419-019-1322-x.

Epidemiologic Analysis Along the Mevalonate Pathway Reveals Improved Cancer Survival in Patients Who Receive Statins Alone and in Combination With Bisphosphonates.

El-Refai S, Brown J, Arnold S, Black E, Leggas M, Talbert J JCO Clin Cancer Inform. 2019; 1:1-12.

PMID: 30657380 PMC: 6467073. DOI: 10.1200/CCI.17.00010.

The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer.

Bhardwaj A, Singh H, Trinidad C, Albarracin C, Hunt K, Bedrosian I Breast Cancer Res. 2018; 20(1):150.

PMID: 30537987 PMC: 6290546. DOI: 10.1186/s13058-018-1074-z.

References

1.

Clendening J, Pandyra A, Boutros P, El Ghamrasni S, Khosravi F, Trentin G . Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci U S A. 2010; 107(34):15051-6. PMC: 2930553. DOI: 10.1073/pnas.0910258107. View

2.

Ahern T, Pedersen L, Tarp M, Cronin-Fenton D, Garne J, Silliman R . Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst. 2011; 103(19):1461-8. PMC: 3186780. DOI: 10.1093/jnci/djr291. View

3.

Clendening J, Pandyra A, Li Z, Boutros P, Martirosyan A, Lehner R . Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma. Blood. 2010; 115(23):4787-97. DOI: 10.1182/blood-2009-07-230508. View

4.

Clendening J, Penn L . Targeting tumor cell metabolism with statins. Oncogene. 2012; 31(48):4967-78. DOI: 10.1038/onc.2012.6. View

5.

Pandyra A, Mullen P, Kalkat M, Yu R, Pong J, Li Z . Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop. Cancer Res. 2014; 74(17):4772-82. DOI: 10.1158/0008-5472.CAN-14-0130. View

6.

Freed-Pastor W, Mizuno H, Zhao X, Langerod A, Moon S, Rodriguez-Barrueco R . Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 2012; 148(1-2):244-58. PMC: 3511889. DOI: 10.1016/j.cell.2011.12.017. View

7.

Garwood E, Kumar A, Baehner F, Moore D, Au A, Hylton N . Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2009; 119(1):137-44. PMC: 4087110. DOI: 10.1007/s10549-009-0507-x. View

8.

Advani A, McDonough S, Copelan E, Willman C, Mulford D, List A . SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. Br J Haematol. 2014; 167(2):233-7. PMC: 4188732. DOI: 10.1111/bjh.13035. View

9.

Kita T, Brown M, Goldstein J . Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. J Clin Invest. 1980; 66(5):1094-100. PMC: 371547. DOI: 10.1172/JCI109938. View

10.

Bjarnadottir O, Romero Q, Bendahl P, Jirstrom K, Ryden L, Loman N . Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat. 2013; 138(2):499-508. DOI: 10.1007/s10549-013-2473-6. View

Targeting Tumor Cell Metabolism Via the Mevalonate Pathway: Two Hits Are Better Than One